(Q40026210)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

Federica Di Nicolantonio

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sabrina Arena

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Giulia Siravegna

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Benedetta Mussolin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Alberto Bardelli

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

8

Andrea Bertotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Jeffrey D Kearns

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Beni B Wolf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sandra Misale

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Luca Lazzari

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Livio Trusolino

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Alex A Adjei

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Clara Montagut

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Rachel Nering

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

1 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

324

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

324ra14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26843189%20AND%20SRC:MED&resulttype=core&format=json

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Detection of circulating tumor DNA in early- and late-stage human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

The genomic landscape of response to EGFR blockade in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Imatinib and beyond--exploring the full potential of targeted therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Rociletinib in EGFR-mutated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAD5640